0.212  -0.009 (-4.07%)		02-20 16:00
Open: 0.233 High: 0.233 Volume: 555,054		Pre. Close: 0.221 Low: 0.2111 Market Cap: 11(M)

Short term
Mid term
Targets	6-month :	0.37	1-year :	0.45
Resists	First :	0.31	Second :	0.38
Pivot price	0.28
Supports	First :	0.2	Second :	0.16
MAs	MA(5) :	0.24	MA(20) :	0.29
	MA(100) :	0.46	MA(250) :	0.78
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	8.7	D(3) :	8.7
RSI	RSI(14): 26.9
52-week	High :	1.52	Low :	0.2

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ITRM ] has closed below the lower bollinger band by 2.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ITRM ] is to continue within current trading range. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.23 - 0.24	0.24 - 0.24
Low:	0.21 - 0.21	0.21 - 0.21
Close:	0.21 - 0.21	0.21 - 0.22

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Fri, 20 Feb 2026
Iterum Therapeutics PLC expected to post a loss of 14 cents a share - Earnings Preview - TradingView

Wed, 18 Feb 2026
Iterum Therapeutics Shareholders Reject Key Capital Proposals - TipRanks

Wed, 18 Feb 2026
Iterum Therapeutics (NASDAQ: ITRM) flags going‑concern risk after failed capital votes - Stock Titan

Fri, 13 Feb 2026
Iterum Therapeutics Announces Expanded Market Access and Patent Protection for ORLYNVAH™ - Quiver Quantitative

Thu, 12 Feb 2026
Iterum Therapeutics Provides Business Update - Bitget

Wed, 17 Dec 2025
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	53 (M)
Held by Insiders	5.237e+007 (%)
Held by Institutions	0.7 (%)
Shares Short	1,760 (K)
Shares Short P.Month	0 (K)

EPS	-1.932e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	982.3 %
Return on Equity (ttm)	-53.3 %
Qtrly Rev. Growth	390000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	40559.4
Qtrly Earnings Growth	-0.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-4.05

Dividend	0
Forward Dividend	1.58e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.